AstraZeneca PLC (LON: AZN)
London
· Delayed Price · Currency is GBP · Price in GBX 11,046
+6 (0.05%)
Jan 23, 2025, 5:32 PM BST
AstraZeneca Revenue
AstraZeneca had revenue of $13.57B USD in the quarter ending September 30, 2024, with 18.04% growth. This brings the company's revenue in the last twelve months to $51.21B, up 13.81% year-over-year. In the year 2023, AstraZeneca had annual revenue of $45.81B with 3.29% growth.
Revenue (ttm)
$51.21B
Revenue Growth
+13.81%
P/S Ratio
4.48
Revenue / Employee
$569.59K
Employees
89,900
Market Cap
171.27B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 45.81B | 1.46B | 3.29% |
| Dec 31, 2022 | 44.35B | 6.93B | 18.53% |
| Dec 31, 2021 | 37.42B | 10.80B | 40.58% |
| Dec 31, 2020 | 26.62B | 2.23B | 9.16% |
| Dec 31, 2019 | 24.38B | 2.29B | 10.38% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| ConvaTec Group | 1.74B |
| Hikma Pharmaceuticals | 2.39B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |
| Indivior | 881.89M |
AstraZeneca News
- 43 minutes ago - Levi & Korsinsky Notifies Shareholders of AstraZeneca PLC (AZN) of a Class Action Lawsuit and an Upcoming Deadline - Accesswire
- 1 hour ago - Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 21, 2025 in AstraZeneca PLC Lawsuit - AZN - Accesswire
- 2 hours ago - February 21, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against AZN - Accesswire
- 2 hours ago - AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit with the Schall Law Firm - PRNewsWire
- 2 hours ago - The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against AstraZeneca PLC - Accesswire
- 4 hours ago - AstraZeneca PLC Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your Rights - AZN - Accesswire
- 4 hours ago - AstraZeneca (AZN) Faces Securities Class Action After Reports of PRC Probe into Fraud and Corruption - Hagens Berman - Accesswire
- 5 hours ago - Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025 - AZN - Accesswire